Home > Publications database > Comparison of hybrid (68)Ga-PSMA PET/MRI and (68)Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer. > print |
001 | 125848 | ||
005 | 20240228143336.0 | ||
024 | 7 | _ | |a 10.1007/s00259-015-3206-3 |2 doi |
024 | 7 | _ | |a pmid:26508290 |2 pmid |
024 | 7 | _ | |a 0340-6997 |2 ISSN |
024 | 7 | _ | |a 1432-105X |2 ISSN |
024 | 7 | _ | |a 1619-7070 |2 ISSN |
024 | 7 | _ | |a 1619-7089 |2 ISSN |
024 | 7 | _ | |a altmetric:4700482 |2 altmetric |
037 | _ | _ | |a DKFZ-2017-01972 |
041 | _ | _ | |a eng |
082 | _ | _ | |a 610 |
100 | 1 | _ | |a Freitag, Martin |0 P:(DE-He78)c420f6efccb409e1a287be027501a74c |b 0 |e First author |u dkfz |
245 | _ | _ | |a Comparison of hybrid (68)Ga-PSMA PET/MRI and (68)Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer. |
260 | _ | _ | |a Heidelberg [u.a.] |c 2016 |b Springer-Verl. |
336 | 7 | _ | |a article |2 DRIVER |
336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1524733420_25151 |2 PUB:(DE-HGF) |
336 | 7 | _ | |a ARTICLE |2 BibTeX |
336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
520 | _ | _ | |a To evaluate the reproducibility of the combination of hybrid PET/MRI and the (68)Ga-PSMA-11 tracer in depicting lymph node (LN) and bone metastases of prostate cancer (PC) in comparison with that of PET/CT.A retrospective analysis of 26 patients who were subjected to (68)Ga-PSMA PET/CTlow-dose (1 h after injection) followed by PET/MRI (3 h after injection) was performed. MRI sequences included T1-w native, T1-w contrast-enhanced, T2-w fat-saturated and diffusion-weighted sequences (DWIb800). Discordant PET-positive and morphological findings were evaluated. Standardized uptake values (SUV) of PET-positive LNs and bone lesions were quantified and their morphological size and conspicuity determined.Comparing the PET components, the proportion of discordant PSMA-positive suspicious findings was very low (98.5 % of 64 LNs concordant, 100 % of 28 bone lesions concordant). Two PET-positive bone metastases could not be confirmed morphologically using CTlow-dose, but could be confirmed using MRI. In 12 of 20 patients, 47 PET-positive LNs (71.9 %) were smaller than 1 cm in short axis diameter. There were significant linear correlations between PET/MRI SUVs and PET/CT SUVs in the 64 LN metastases (p < 0.0001) and in the 28 osseous metastases (p < 0.0001) for SUVmean and SUVmax, respectively. The LN SUVs were significantly higher on PET/MRI than on PET/CT (p SUVmax < 0.0001; p SUVmean < 0.0001) but there was no significant difference between the bone lesion SUVs (p SUVmax = 0.495; p SUVmean = 0.381). Visibility of LNs was significantly higher on MRI using the T1-w contrast-enhanced fat-saturated sequence (p = 0.013), the T2-w fat-saturated sequence (p < 0.0001) and the DWI sequence (p < 0.0001) compared with CTlow-dose. For bone lesions, only the overall conspicuity was higher on MRI compared with CTlow-dose (p < 0.006).Nodal and osseous metastases of PC are accurately and reliably depicted by hybrid PET/MRI using (68)Ga-PSMA-11 with very low discordance compared with PET/CT including PET-positive LNs of normal size. The correlation between PET/MRI SUVs and PET/CT SUVs was linear in LN and bone metastases but was significantly lower in control (non-metastatic) tissue. |
536 | _ | _ | |a 315 - Imaging and radiooncology (POF3-315) |0 G:(DE-HGF)POF3-315 |c POF3-315 |f POF III |x 0 |
588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
650 | _ | 7 | |a Glu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC)) |2 NLM Chemicals |
650 | _ | 7 | |a Oligopeptides |2 NLM Chemicals |
650 | _ | 7 | |a Edetic Acid |0 9G34HU7RV0 |2 NLM Chemicals |
700 | 1 | _ | |a Radtke, Jan Philipp |0 P:(DE-He78)79897f8897ff77676549d9895258a0f2 |b 1 |u dkfz |
700 | 1 | _ | |a Hadaschik, Boris A |b 2 |
700 | 1 | _ | |a Kopp-Schneider, Annette |0 P:(DE-He78)bb6a7a70f976eb8df1769944bf913596 |b 3 |u dkfz |
700 | 1 | _ | |a Eder, Matthias |0 P:(DE-He78)331382460d902d1341dc73db8b990f97 |b 4 |u dkfz |
700 | 1 | _ | |a Kopka, Klaus |0 P:(DE-He78)9793347ba83f527b81a22ab75af9378a |b 5 |u dkfz |
700 | 1 | _ | |a Haberkorn, Uwe |0 P:(DE-He78)13a0afba029f5f64dc18b25ef7499558 |b 6 |u dkfz |
700 | 1 | _ | |a Röthke, Matthias |0 P:(DE-He78)3d11afed6b72f876ad1bba9418e30dac |b 7 |u dkfz |
700 | 1 | _ | |a Schlemmer, Heinz-Peter |0 P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec |b 8 |u dkfz |
700 | 1 | _ | |a Afshar-Oromieh, Ali |0 P:(DE-He78)440aad6e9a60396ff0bcd7c2862db18c |b 9 |e Last author |u dkfz |
773 | _ | _ | |a 10.1007/s00259-015-3206-3 |g Vol. 43, no. 1, p. 70 - 83 |0 PERI:(DE-600)2098375-X |n 1 |p 70 - 83 |t European journal of nuclear medicine and molecular imaging |v 43 |y 2016 |x 1619-7089 |
909 | C | O | |o oai:inrepo02.dkfz.de:125848 |p VDB |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)c420f6efccb409e1a287be027501a74c |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)79897f8897ff77676549d9895258a0f2 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)bb6a7a70f976eb8df1769944bf913596 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)331382460d902d1341dc73db8b990f97 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)9793347ba83f527b81a22ab75af9378a |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-He78)13a0afba029f5f64dc18b25ef7499558 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 7 |6 P:(DE-He78)3d11afed6b72f876ad1bba9418e30dac |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 P:(DE-He78)440aad6e9a60396ff0bcd7c2862db18c |
913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-315 |2 G:(DE-HGF)POF3-300 |v Imaging and radiooncology |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
914 | 1 | _ | |y 2016 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |
915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |
915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b EUR J NUCL MED MOL I : 2015 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b EUR J NUCL MED MOL I : 2015 |
920 | 1 | _ | |0 I:(DE-He78)E010-20160331 |k E010 |l Radiologie |x 0 |
920 | 1 | _ | |0 I:(DE-He78)C060-20160331 |k C060 |l Biostatistik |x 1 |
920 | 1 | _ | |0 I:(DE-He78)E030-20160331 |k E030 |l Radiopharmazeutische Chemie |x 2 |
980 | _ | _ | |a journal |
980 | _ | _ | |a VDB |
980 | _ | _ | |a I:(DE-He78)E010-20160331 |
980 | _ | _ | |a I:(DE-He78)C060-20160331 |
980 | _ | _ | |a I:(DE-He78)E030-20160331 |
980 | _ | _ | |a UNRESTRICTED |
Library | Collection | CLSMajor | CLSMinor | Language | Author |
---|